New Amsterdam Partners LLC NY lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 8.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 34,734 shares of the biotechnology company’s stock after selling 3,277 shares during the quarter. New Amsterdam Partners LLC NY owned 0.08% of United Therapeutics Corporation worth $4,070,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of United Therapeutics Corporation by 3.3% during the 2nd quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock valued at $635,330,000 after purchasing an additional 155,349 shares during the last quarter. FMR LLC increased its position in shares of United Therapeutics Corporation by 2.8% during the 2nd quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock valued at $551,980,000 after purchasing an additional 116,062 shares during the last quarter. Vanguard Group Inc. increased its position in shares of United Therapeutics Corporation by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock valued at $494,291,000 after purchasing an additional 25,047 shares during the last quarter. State Street Corp increased its position in shares of United Therapeutics Corporation by 0.9% during the 2nd quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock valued at $261,345,000 after purchasing an additional 17,179 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of United Therapeutics Corporation by 5.3% during the 2nd quarter. Acadian Asset Management LLC now owns 1,142,056 shares of the biotechnology company’s stock valued at $148,160,000 after purchasing an additional 57,509 shares during the last quarter.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. Jefferies Group LLC restated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a report on Friday, July 14th. TheStreet cut United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Cowen and Company restated a “hold” rating and set a $129.00 price objective on shares of United Therapeutics Corporation in a report on Friday, October 27th. Finally, HC Wainwright restated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, October 26th. Five analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $132.82.

In other United Therapeutics Corporation news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total transaction of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,232 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total value of $164,250.24. Following the sale, the chief executive officer now directly owns 2,301 shares of the company’s stock, valued at approximately $306,769.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,969 shares of company stock worth $2,358,212. Company insiders own 7.80% of the company’s stock.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up $0.62 during trading hours on Wednesday, reaching $122.92. The company had a trading volume of 12,409 shares, compared to its average volume of 420,992. United Therapeutics Corporation has a 12 month low of $112.01 and a 12 month high of $169.89. The firm has a market cap of $5,272.18, a price-to-earnings ratio of 10.76 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The firm had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. During the same quarter in the prior year, the business earned $4.23 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. research analysts expect that United Therapeutics Corporation will post 11.92 EPS for the current year.

WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/08/new-amsterdam-partners-llc-ny-has-4-07-million-stake-in-united-therapeutics-corporation-uthr.html.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.